Navigation Links
Small Increase in Diabetes Risk Noted in Statin Patients
Date:2/16/2010

For many, benefits of lowering cholesterol outweigh drugs' downsides, researchers say

TUESDAY, Feb. 16 (HealthDay News) -- The use of cholesterol-lowering statin drugs increases the chance of developing diabetes by 9 percent, but the absolute risk is low, especially when compared with how much statins reduce the threat of heart disease and heart attack, new research shows.

The researchers analyzed data from 13 clinical trials of statins conducted between 1994 and 2009. The trials included a total of 91,140 people. Of those, 2,226 participants taking statins and 2,052 people in control groups developed diabetes over an average of four years.

Overall, statin therapy was associated with a 9 percent increased risk of developing diabetes, but the risk was higher in older patients. Neither body mass index nor changes in LDL (bad) cholesterol levels appeared to affect the statin-associated risk of developing diabetes.

There's no evidence that statin therapy raises diabetes risk through a direct molecular mechanism, but this may be a possibility, said study authors Naveed Satar and David Preiss, of the University of Glasgow's Cardiovascular Research Center, and colleagues.

The researchers noted that slightly improved survival among patients taking statins doesn't explain the increased risk of developing diabetes. They added that while it's highly unlikely, the increased risk of diabetes among people taking statins could be a chance finding.

To put their findings in context, the study authors pointed out that if 255 patients took statins for four years, there would be only one extra case of diabetes. However, for each millimole per liter reduction in LDL cholesterol achieved by taking statins, the same 255 patients would experience five fewer major coronary events, such as coronary heart disease death or non-fatal heart attack.

"In view of the overwhelming benefit of statins for reduction of cardiovascular events, the small absolute risk for development of diabetes is outweighed by cardiovascular benefit in the short and medium term in individuals for whom statin therapy is recommended," the researchers wrote in a news release.

"We therefore suggest that clinical practice for statin therapy does not need to change for patients with moderate or high cardiovascular risk or existing cardiovascular disease. However, the potentially raised diabetes risk should be taken into account if statin therapy is considered for patients at low cardiovascular risk or patient groups in which cardiovascular benefit has not been proven," they concluded.

The study authors also recommended monitoring of older people taking statins, since they have a higher risk of developing diabetes.

The findings were published online Feb. 16 and will appear in an upcoming print issue of The Lancet.

The benefit of taking statins to reduce cardiovascular risk greatly outweighs the risk of developing diabetes by a ratio of about 9:1, Dr. Christopher P. Cannon, of the cardiovascular division at Brigham and Women's Hospital and Harvard Medical School in Boston, wrote in an accompanying comment article.

"Nonetheless, this newly identified risk does warrant monitoring, and as such, in addition to periodic monitoring of liver-function tests and creatine kinase, it seems reasonable to add glucose to the list of tests to monitor in older patients on statins," Cannon said.

More information

The U.S. Food and Drug Administration has more about statins.



-- Robert Preidt



SOURCE: The Lancet, news release, Feb. 16, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
3. IPC The Hospitalist Company, Inc. to Present at Deutsche Bank 2010 Small and Mid Cap Conference
4. Omnetics Nano-to-Flex Connectors Solve Big Problems in Small Spaces
5. Even a Small Dietary Reduction in Salt Could Mean Fewer Heart Attacks, Strokes and Deaths
6. Small Cuts in Salt Intake Spur Big Drops in Heart Trouble
7. NSBA 2009 Year-End Economic Report: Small Businesses Still Struggling
8. Union Tax Deal a Slap in the Face to Small Business
9. NSBA Unveils Small Business Health Care Reform Checklist
10. Small Businesses In Singapore Outmarkets & Outperforms Bigger Players in Tough Economy With Online Marketing
11. 83 Percent of Small Businesses Say No to Health Care Public Option, 89 Percent Say Government Cannot Provide Adequate Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: